Why did Danaher rise on 5 October?
Written after the close on
Danaher +3.34%
Danaher rose sharply in the latest session, likely helped by renewed interest in its valuation and growth story. Over the last five trading days it fell slightly, moving against a rising market but in line with a clearly weaker healthcare sector. The likely driver was the leadership handoff: Julie Sawyer Montgomery became president and CEO on October 1, while former CEO Rainer Blair stays on as senior advisor through March 2027, a change first flagged in August. That came as biopharma customers deferred roughly $100 million of bioprocessing equipment and resin shipments into 2027, and the shares also traded without their dividend last week, which trims the quoted price. Watch the late-October earnings report, where management's read on backlog conversion and core growth will matter most.
Next report: · Add to calendar · Google Calendar